Yahoo
NSE - Delayed Quote INR

Caplin Point Laboratories Limited (CAPLIPOINT.NS)

2,331.00 -45.10 (-1.90%)
At close: October 30 at 3:29:59 PM GMT+5:30
Chart Range Bar
Loading chart for CAPLIPOINT.NS
  • Previous Close 2,376.10
  • Open 2,377.40
  • Bid --
  • Ask --
  • Day's Range 2,310.00 - 2,422.40
  • 52 Week Range 1,500.30 - 2,990.00
  • Volume 128,339
  • Avg. Volume 179,129
  • Market Cap (intraday) 177.183B
  • Beta (5Y Monthly) 0.42
  • PE Ratio (TTM) 26.71
  • EPS (TTM) 87.28
  • Earnings Date (est.) --
  • Forward Dividend & Yield 8.00 (0.34%)
  • Ex-Dividend Date Sep 18, 2026
  • 1y Target Est 2,765.00

Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel, capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag, inhalers, and sprays and IV infusion. It also provides dry and syrups, lyophilized vials, prefilled syringes, emulsion injection, ophthalmic droppers, sachets, liquid injectables, topicals, pre-filled syringes, and pre-mix bags. Caplin Point Laboratories Limited was incorporated in 1990 and is headquartered in Chennai, India.

www.caplinpoint.net

4,199

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

CAPLIPOINT.NS
27.26%
S&P BSE SENSEX (^BSESN)
12.63%

1-Year Return

CAPLIPOINT.NS
15.20%
S&P BSE SENSEX (^BSESN)
11.78%

3-Year Return

CAPLIPOINT.NS
131.86%
S&P BSE SENSEX (^BSESN)
16.14%

5-Year Return

CAPLIPOINT.NS
189.61%
S&P BSE SENSEX (^BSESN)
25.55%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY27
Revenue 6.1B
Earnings 1.77B
Profit Margin 28.98%

Q1

FY26

Q2

FY26

Q3

FY26

Q1

FY27

0
2B
4B
6B
29.0%
29.5%
30.0%

Analyst Insights

View More

Analyst Price Targets

2,690.00
2,765.00 Average
2,331.00 Current
2,840.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    29.09%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    22.87B

  • Net Income Avi to Common (ttm)

    6.65B

  • Diluted EPS (ttm)

    87.28

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    10.07B

  • Total Debt/Equity (mrq)

    0.13%

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: